Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Deadline Approaching: Apply for the Fierce AI Innovation Awards
Biotech
Biotech
ADA: Novo CSO says ‘jury still out’ on CagriSema v. retatrutide
It's too early to say whose next-gen incretin stands supreme between Novo Nordisk’s CagriSema and Eli Lilly’s retatrutide, Novo’s CSO told Fierce.
Fraiser Kansteiner
Jun 10, 2026 11:10am
GLP-1s may combat depression through a mood-boosting gut microbe
Jun 10, 2026 11:00am
How AI is reshaping biopharma decision-making
Brought to you by
Clarivate
Big Pharma-backed SonoThera sounds off with $125M series B
Jun 10, 2026 10:48am
Managing complexity across biopharma modalities
Brought to you by
SK Pharmteco
Ethyreal Bio raises $101M, joining biotechs gunning for Tepezza
Jun 10, 2026 9:35am